Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 3/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 3/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3841342 | 0.92 | P2RX7 (0.52) | KCNQ3KCNQ2P2RX7ALDH1A1 | |
| SCHEMBL3843919 | 0.92 | P2RX7 (0.52) | KCNQ3KCNQ2P2RX7ALDH1A1 | |
| SCHEMBL3836999 | 0.88 | P2RX7 (0.50) | KCNQ3KCNQ2P2RX7HSD11B1IDH1 | |
| SCHEMBL13813697 | 0.87 | P2RX7 (0.55) | KCNQ3KCNQ2P2RX7PTGER4GBA1 | |
| SCHEMBL1803661 | 0.87 | P2RX7 (0.55) | KCNQ3KCNQ2P2RX7PTGER4GBA1 | |
| SCHEMBL1803060 | 0.84 | P2RX7 (0.44) | KCNQ3KCNQ2P2RX7PTGER4GBA1 | |
| SCHEMBL4510059 | 0.84 | P2RX7 (0.51) | P2RX7 | |
| SCHEMBL4510063 | 0.84 | P2RX7 (0.51) | P2RX7 | |
| SCHEMBL1807288 | 0.81 | P2RX7 (0.49) | KCNQ3KCNQ2P2RX7PTGER4GBA1 | |
| SCHEMBL5822305 | 0.81 | P2RX7 (0.45) | KCNQ3KCNQ2P2RX7PTGER4GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633717-B1 | P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | ASTRAZENECA AB (SE) | 2009-10-28 | — | — | EP | disclosed |
| US-20090143354-A1 | P2X7 Receptor Antagonists and Their Use | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | US | disclosed |
| US-7408065-B2 | P2X7 receptor antagonists and their use | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| US-20060293337-A1 | P2x7 receptor antagonists and their use | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | US | disclosed |
| EP-1633717-A1 | NEW P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004106305-A1 | NEW P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293337-A1 | P2x7 receptor antagonists and their use | P2RX7, P2RX1, P2RX2 | KCNQ3 234/4885KCNQ2 159/4885P2RX7 1/4885 |
| US-20090143354-A1 | P2X7 Receptor Antagonists and Their Use | P2RX7, P2RX1, P2RX2 | KCNQ3 234/4885KCNQ2 159/4885P2RX7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.